Generated September 24, 2026 at 8:31 PM ET
· Covers September 24 trading day
· 10 of 170 ready 8-Ks selected
· AI-assisted overview
The day's filings featured major M&A moves: Select Water Solutions agreed to acquire Pilot Water for $700M plus earnout, Iridium shareholders approved a $54/share Rocket Lab acquisition, and Bravo Multinational issued preferred shares giving MWP ~77% control. Debt-related actions included Jaguar Health issuing shares to cut a $5.05M note, America's Car-Mart extending lender waivers while flagging bankruptcy risk, and Sysco entering underwriting for $10.75B USD, C$1.5B, and €1B note issuance. Regulatory and trial updates came from aTyr Pharma reaching FDA alignment on a Phase 3 protocol, Acadia's Phase 2 remlifanserin missing primary endpoint but supporting Phase 3, and Beacon Topco reporting positive balomenib data while extending its merger deadline. Live Oak Acquisition Corp. VI completed a $230M IPO. Overall, the filings are diverse across M&A, financing, and clinical developments.
debt
negative
materiality 0.85
September 24, 2026, 6:01 AM ET
Jaguar Health issues 547,898 shares to cut $5.05M of 2025 Streeterville note
- Exchanged 547,898 common shares for $5,049,909 reduction in $10.81M secured note to Streeterville Capital.
- Shares issued under Section 3(a)(9); no cash paid, shares to become free-trading after Rule 144 holding period tacking.
- Post-exchange share count ~1,281,867; issuance adds ~74.6% to prior outstanding stock.
WTTR
Select Water Solutions, Inc.
M&A
positive
materiality 0.85
September 24, 2026, 4:45 PM ET
Select Water buys Pilot Water for $600M cash + $100M stock, plus $15M earnout
- Acquires Pilot Water Solutions, private Delaware Basin water midstream, for $700M cash/stock plus $15M contingent earnout.
- Pilot Water 2026E Adjusted EBITDA $100–110M, growing to $120–130M in 2027; targets $10–15M cost synergies.
- Adds 2.7M bbl/day permitted disposal, 0.9M undeveloped, 700+ miles pipeline; combined MVCs >600k bbl/day.
IRDM
Iridium Communications Inc.
M&A
positive
materiality 0.80
September 24, 2026, 4:52 PM ET
Iridium shareholders approve Rocket Lab acquisition; $54/share notional value
- 85,862,105 votes for merger agreement (99.6% of votes cast); 318,415 against, 67,862 abstain.
- Stockholders to receive $27 cash plus Rocket Lab shares, notional value $54 per share.
- Transaction expected to close by mid-2027, pending regulatory approvals and closing conditions.
BRVO
Bravo Multinational Inc.
M&A
neutral
materiality 1.00
September 24, 2026, 4:19 PM ET
Bravo Multinational issues 1.62M preferred shares to MWP, giving MWP ~77% control
- Issued 1,621,026 Series A Preferred shares to MWP for $3.161M (licenses $2.5M, cash $400k, debt forgiveness $261k).
- Preferred converts to 162.1M common shares; MWP holds ~76.7% as-converted (82.9% if option exercised).
- Option for additional $1.5M preferred shares exercisable through Sept 18, 2027.
regulatory
positive
materiality 0.70
September 24, 2026, 7:47 AM ET
aTyr Pharma reaches FDA alignment on Phase 3 protocol for efzofitimod in pulmonary sarcoidosis
- Study to start Q4 2026; global, randomized, double-blind, placebo-controlled, 54-week trial.
- Two parallel cohorts: 5.0 mg/kg efzofitimod vs placebo IV every 3 weeks for 17 doses; up to 372 patients.
- Primary endpoint: change from baseline FVC at week 48; key secondary: KSQ-Lung score change at week 48.
CRMT
AMERICAS CARMART INC
debt
negative
materiality 0.80
September 24, 2026, 4:05 PM ET
America's Car-Mart extends lender waiver to Oct 1, flags bankruptcy risk
- Lenders (Silver Point agent) extended Scheduled Termination Date and covenant relief (liquidity, collateral coverage) through Oct 1, 2026.
- Company previously received extensions on Sept 4, 11, 18 and June 25; defaults under Credit Agreement waived temporarily.
- Evaluating strategic alternatives incl. financing, recapitalization, restructuring, M&A; no assurance of favorable outcome.
—
Live Oak Acquisition Corp. VI
other material
positive
materiality 0.90
September 24, 2026, 4:30 PM ET
Live Oak Acquisition Corp. VI completes $230M IPO; units trade on Nasdaq
- IPO of 23,000,000 units at $10.00/unit, including full over-allotment; gross proceeds $230,000,000.
- Trust account funded with $230,000,000; funds held until business combination or redemption (21-24 month window).
- Sponsor purchased 4,600,000 private placement warrants at $1.00 each, totaling $4,600,000.
ACAD
ACADIA PHARMACEUTICALS INC
other material
positive
materiality 0.80
September 24, 2026, 5:11 PM ET
Acadia Phase 2 RADIANT: remlifanserin 60mg misses primary endpoint (p=0.0603) but supports Phase 3
- Primary SAPS-H+D: 60mg change -12.6 vs placebo -10.4 (week 6), effect size 0.26, p=0.0603.
- Key secondary CGI-S-ADP: 60mg change -1.3 vs -0.9, effect size 0.37, p=0.0077 (nominal).
- 30mg dose minimal improvement; company to amend Phase 3 to remove 30mg arm.
other material
positive
materiality 0.80
September 24, 2026, 9:19 AM ET
Balomenib Phase 1b shows durable HbA1c improvement; Merger closing extended to Oct 31
- Merger closing date for Clywedog acquisition amended to Oct 31, 2026 (or earlier mutual agreement); End Date also Oct 31, 2026.
- Phase 1b: placebo-adjusted HbA1c -0.77% at Week 12 (p<0.01) and -0.70% at Week 16 (p<0.05) after 3-week dosing.
- OGTT: placebo-adjusted reductions in total glucose AUC 203 mmol·min/L (p=0.019), peak glucose 2.03 mmol/L (p=0.013), 2-hr glucose 2.46 mmol/L (p=0.010).
—
Sysco Holdings Corp
debt
neutral
materiality 0.75
September 24, 2026, 5:22 PM ET
Sysco enters underwriting agreements for $10.75B USD notes, C$1.5B CAD and €1B EUR
- USD senior notes: $10.75B across 7 tranches (2029-2066), coupons 5.450%-6.600%.
- CAD senior notes: C$1.5B (4.250% due 2030, 4.800% due 2034) and EUR junior subordinated €1B 6.000% due 2056.
- USD junior subordinated notes: $3.9B (Series A/B/C at 7.100%/7.250%/7.350%) due 2056.